Navigation Links
United States Anesthesia and Respiratory Devices Market Outlook to 2017 - Respiratory Devices, Respiratory Measurement Devices, Airway and Anesthesia Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others
Date:12/13/2011

tems Overall Revenue (2003-2017) 246

11.5 Sleep Apnea Diagnostic Systems Overall Volume (2003-2017) 250

11.6 Sleep Apnea Diagnostic Systems Average Price (2003-2017) 254

11.7 Sleep Apnea Diagnostic Systems Distribution Share (2009-2010) 255

11.8 Sleep Apnea Diagnostic Systems, United States, Company share (2009-2010) 256

12 Overview of Key Companies in United States Anesthesia and Respiratory Devices Market 258

12.1 Philips Respironics, Inc. 258

12.2 Covidien plc 259

12.3 ResMed Inc. 260

12.4 CareFusion Corporation 261

12.5 GE Healthcare 262

12.6 Draegerwerk AG & Co. KGaA 263

12.7 Smiths Medical 264

12.8 Teleflex Incorporated 264

12.9 Masimo Corporation 264

12.10 Fisher & Paykel Healthcare Corporation Limited 265

12.11 B. Braun Medical Inc. 265

12.12 HAMILTON MEDICAL AG 265

12.13 MAQUET GmbH & Co. KG 266

12.14 Becton, Dickinson and Company 266

12.15 Oridion Systems Ltd. 266

12.16 LMA International N.V. 267

12.17 King Systems Corporation 267

12.18 Medline Industries, Inc. 267

12.19 Nonin Medical, Inc. 267

12.20 OSI Systems, Inc. 268

12.21 Ambu A/S 268

12.22 Intersurgical Ltd. 268

12.23 I-Flow Corporation 269

12.24 Embla Systems LLC 269

12.25 Natus Medical Incorporated 269

12.26 Astro-Med, Inc. 270

12.27 Mindray Medical International Limited 270

12.28 Compumedics Limited 270

12.29 Vincent Medical Mfg. Co., Ltd. 271

12.30 Stryker Corporation 271

12.31 Baxter International Inc. 271

12.32 DJO Finance LLC 272

13 Anesthesia and Respiratory Devices Market Pipeline Products 273

14 Financial Deals Landscape 277

14.1 Acquisition 277

14.2 Partnerships 288

15 Recent Developments 294

15.1 Strategy And Business Planning 294

15.2 Legal and Regulatory 297

15.3 G
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Zimmer Introduces New CLS® Brevius™ Hip Stem with Kinectiv® Technology in the United States
2. TRACE Releases Report on Bribe Demands in the United States
3. Proventixs nGage™ the Most Widely Used Automated Healthcare Hand Hygiene Monitoring System in the United States
4. AcceleDent™ System, Used for Accelerated Orthodontic Tooth Movement, Receives United States FDA Clearance
5. United Spinal Secures Leading Public Policy and Durable Medical Equipment Specialist: Alex Bennewith is New Director of Government Relations
6. United Seating & Mobility Reaches Agreement to Acquire The Rehab Specialist of North Carolina
7. Astellas Signs United Nations Global Compact
8. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
9. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
10. United States Diagnostic Imaging Market Outlook to 2017 - Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others
11. Reed V. Tuckson, M.D., Executive Vice President and Chief of Medical Affairs at UnitedHealth Group, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Simplified Genetics , ... improved fitness, health and safety in the U.S., announced today ... personal roadmap to improved overall health found within specific genes ... your cheek. The tests include Simply ... a full sequence genetic analysis that maps four key genes ...
(Date:9/2/2015)... ROCKVILLE, Md. , Sept. 2, 2015 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... J.J. Finkelstein , President and Chief Executive ... Rodman & Renshaw Global Investment Conference, sponsored by ... will be held September 8-10, 2015 at the ...
(Date:9/2/2015)...  MGC Diagnostics Corporation (NasdaqCM: MGCD), a global medical ... its financial results for the third quarter of fiscal ... at 4:30 p.m. ET on Thursday, September 10, 2015. ... quarter of fiscal 2015 after the markets close on ... dial (877) 317-6789 or (412) 317-6789 to access the ...
Breaking Medicine Technology:Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 2Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 3RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2
... KineMed Inc., a,pathway-based drug discovery and development ... of an investigational agent,to regenerate nerve cells in ... cognition and mood. The agent, part of a ... a behavioral test in a,preclinical model. The findings ...
... am ET, BEDMINSTER, N.J., Oct. 11 ... top-line results from,the company,s Phase 3 study of ... 83 patients with short bowel,syndrome (SBS) received either ... dose (0.10 mg/kg/day) or placebo. The,clinical efficacy endpoint ...
Cached Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 2Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 4Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 5Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 6Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 7
(Date:9/2/2015)... , ... September 02, 2015 , ... Based in Beverly ... fleet of truly superb luxury vehicles based on which of the latest and greatest ... the latest step forward in pursuit of this goal: a 2015 Rolls Royce ...
(Date:9/2/2015)... DC (PRWEB) , ... September 02, 2015 , ... Telehealth ... American Well Corp., contracted to handle the telehealth services of more than 12 Blues ... Cross and Blue Shield Plans takes a look this growing trend, interviewing executives at ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and ... gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. ...
(Date:9/2/2015)... Fort Lauderdale, FL (PRWEB) , ... September 02, ... ... cost for Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision ... with hospitalized Medicare patients – is likely to average approximately $71,000 or roughly ...
(Date:9/2/2015)... Bryn Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Location: Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, ... justCommunity, Inc., will host a day-long seminar featuring New York Times best-selling author Sam ...
Breaking Medicine News(10 mins):Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2
... women,s risk gets even smaller 10 years after stopping ... News) -- Women taking oral contraceptives are at a ... decade after stopping the pill even this very small ... that finding doesn,t change the recommendation for women to ...
... year over year growth driven by Loestrin 24 and Taclonex; Company ... updates full year 2007 financial guidance, ST. ... today announced its results for the quarter ended,September 30, 2007. Revenue ... of 16.3%, over the prior year quarter. The,primary drivers of the ...
... Highlighted by Continued Momentum in Global Commercialization, Program for Once-Daily ... ... III Study -, LAVAL, QC, Nov. 9 /PRNewswire-FirstCall/ - ... the third quarter of fiscal,2007, ended September 30, 2007. All ...
... event in 2007, net loss stable ... otherwise noted), BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ - ... company, today announced financial results for the first,quarter of ... "We are also focused on the successful completion of ...
... Pharmaceutical product teams,have the power to make ... The problem is,launch teams often lack the right ... only produce a sub-optimal launch. In fact, ... and cross-functional team work are key ingredients,during product ...
... Support Continued Advancement of Novel Technology and ... ... Inc., a,privately-held therapeutic antibody product company, today announced that,it has raised ... A/S.,Additional investors participating significantly in the round were Frazier,Healthcare Ventures and ...
Cached Medicine News:Health News:Pill Poses Little Cervical Cancer Risk 2Health News:Pill Poses Little Cervical Cancer Risk 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 14
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: